background
care
select
test
plasma
reduc
risk
bloodborn
virus
start
materi
plasmaderiv
product
furthermor
effect
measur
pasteur
hour
implement
manufactur
process
therapeut
plasma
protein
human
albumin
coagul
factor
immunoglobulin
enzym
inhibitor
inactiv
bloodborn
virus
concern
comprehens
compil
viru
reduct
capac
pasteur
present
includ
effect
stabil
use
protect
therapeut
protein
modif
heat
treatment
inactiv
kinet
pasteur
broad
rang
virus
evalu
relev
intermedi
differ
plasma
manufactur
process
studi
carri
routin
manufactur
target
variabl
temperatur
productspecif
stabil
composit
addit
studi
also
perform
robust
condit
outsid
product
specif
data
demonstr
pasteur
inactiv
wide
rang
envelop
nonenvelop
virus
divers
physicochem
characterist
maximum
hour
incub
residu
infect
could
detect
major
envelop
virus
effect
inactiv
rang
nonenvelop
virus
except
nonhuman
parvovirus
document
conclus
pasteur
robust
reliabl
viru
inactiv
method
broad
effect
known
bloodborn
pathogen
emerg
potenti
emerg
virus
pasteur
proven
highli
effect
step
combin
complementari
safeti
measur
toward
assur
viru
safeti
final
product
tudi
inactiv
virus
biolog
initi
trigger
case
hepat
report
us
arm
forc
personnel
associ
administr
certain
lot
yellow
fever
vaccin
stabil
nonheattr
human
serum
subsequ
effect
abbrevi
human
parvoviru
bovin
herpesviru
bvdv
bovin
viral
diarrhea
viru
inhibitor
concentr
cpv
canin
parvoviru
dhbv
duck
hepat
b
viru
equin
herpesviru
influenza
viru
human
herpesviru
hsv
herp
simplex
viru
lacv
la
cross
viru
lod
detect
limit
mvm
minut
viru
mice
prv
pseudorabi
viru
strain
phylaxiabartha
rf
reduct
factor
sarscov
sar
coronaviru
sfv
semliki
forest
viru
sinv
sindbi
viru
tbev
tickborn
enceph
tgev
transmiss
gastroenter
coronaviru
wnv
west
nile
viru
yfv
yellow
fever
viru
zikv
zika
viru
inactiv
kinet
pasteur
broad
rang
virus
evalu
relev
intermedi
differ
plasma
manufactur
process
studi
carri
routin
manufactur
target
variabl
temperatur
productspecif
stabil
composit
addit
studi
also
perform
robust
condit
outsid
product
specif
data
demonstr
pasteur
inactiv
wide
rang
envelop
nonenvelop
virus
divers
physicochem
characterist
maximum
hour
incub
residu
infect
could
detect
major
envelop
virus
effect
inactiv
rang
nonenvelop
virus
except
nonhuman
parvovirus
document
conclus
pasteur
robust
reliabl
viru
inactiv
method
broad
effect
known
bloodborn
pathogen
emerg
potenti
emerg
virus
pasteur
proven
highli
effect
step
combin
complementari
safeti
measur
toward
assur
viru
safeti
final
product
tudi
inactiv
virus
biolog
initi
trigger
case
hepat
report
us
arm
forc
personnel
associ
administr
certain
lot
yellow
fever
vaccin
stabil
nonheattr
human
serum
subsequ
effect
global
pathogen
safeti
csl
behr
gmbh
marburg
pasteur
viru
inactiv
techniqu
clinic
demonstr
human
volunt
receiv
either
pasteur
nonheattr
dose
human
serum
albumin
hsa
spike
plasma
contain
infecti
hepat
b
viru
hbv
subject
receiv
pasteur
hbvspike
hsa
display
clinic
sign
infect
monitor
liver
function
assay
contrast
subject
receiv
nonheattr
hbvspike
hsa
plasma
fraction
techniqu
improv
coagul
factor
immunoglobulin
enzym
inhibitor
concentr
isol
industri
scale
larg
volum
pool
plasma
although
therapeut
product
provid
lifesav
lifesustain
therapeut
option
patient
also
intermitt
transmit
bloodborn
virus
especi
hbv
hepat
c
viru
hcv
human
immunodefici
viru
hiv
therefor
method
high
capac
inactiv
andor
remov
virus
integr
industri
manufactur
process
plasmaderiv
product
first
reliabl
viru
inactiv
method
pasteur
heat
treatment
aqueou
solut
hr
effect
inactiv
hbv
hcv
time
call
nonanonb
hepat
viru
coagul
factor
concentr
studi
implement
behringwerk
predecessor
compani
csl
behr
late
earli
employ
suitabl
stabil
condit
permit
pasteur
without
modifi
product
exampl
format
neoantigen
activ
factor
cell
cultur
assay
system
hbv
nonanonb
hepat
viru
avail
capac
pasteur
step
inactiv
hepat
virus
assess
chimpanze
duckl
hiv
known
transmit
blood
transfus
plasmaderiv
product
studi
perform
use
cell
cultur
system
document
heat
sensit
hiv
hemovigil
studi
demonstr
effect
pasteur
step
introduc
manufactur
process
factor
f
viiivon
willebrand
factor
fviii
vwf
concentr
prevent
transmiss
hbv
hcv
nonanonb
hepat
viru
hiv
time
hcv
known
character
viru
donor
screen
assay
avail
hiv
viru
valid
guidelin
ultim
develop
issu
european
author
requir
manufactur
carri
studi
demonstr
capac
reliabl
effect
manufactur
process
inactiv
andor
remov
virus
potenti
present
start
materi
plasma
pool
fraction
guidelin
requir
systemat
evalu
viru
reduct
potenti
manufactur
process
step
viru
valid
studi
employ
relev
model
virus
wide
rang
physicochem
properti
despit
common
usag
pasteur
date
comprehens
publish
overview
effect
pasteur
inactiv
wide
rang
bloodborn
model
virus
variou
plasmaderiv
product
presenc
differ
stabil
composit
avail
summari
present
data
year
viru
valid
studi
includ
viru
inactiv
kinet
perform
target
edg
outsid
manufactur
specif
assess
robust
efficaci
viru
inactiv
pasteur
investig
viru
valid
studi
perform
accord
regulatori
guidelin
stabil
composit
product
pasteur
list
tabl
follow
virus
respect
cell
line
tabl
avail
support
inform
onlin
version
paper
use
pasteur
studi
human
parvoviru
bovin
viru
spike
stock
deriv
viru
master
work
bank
cell
cultur
supernat
contain
viru
harvest
commonli
cell
cultur
medium
without
fetal
bovin
serum
collect
cytopath
effect
detect
viru
stock
clarifi
lowspe
centrifug
remov
cell
debri
aliquot
store
frozen
highertit
viru
stock
requir
concentr
method
gradient
centrifug
employ
initi
titer
log
greater
cell
cultur
infecti
dose
ccid
ml
virus
studi
attain
spike
product
intermedi
hightit
viru
stock
spike
aliquot
least
two
differ
lot
product
intermedi
pasteur
step
perform
accord
manufactur
specif
laboratori
special
design
handl
virus
assess
robust
gener
studi
outsid
manufactur
specif
perform
decreas
temperatur
increas
stabil
concentr
spike
product
intermedi
without
stabil
andor
stabil
excipi
composit
without
plasma
protein
laboratori
scale
pasteur
step
repres
product
scale
specif
product
met
respect
process
variabl
manufactur
scale
exampl
temperatur
incub
time
hour
stabil
composit
product
specif
composit
excipi
concentr
commonli
target
stabil
use
manufactur
process
adjust
stabil
concentr
take
account
viru
spike
volum
viru
reduct
factor
rf
demonstr
therefor
predict
manufactur
process
scale
typic
process
intermedi
obtain
commerci
manufactur
process
spike
viru
mix
thoroughli
divid
tube
immers
water
bath
commonli
stabil
ad
process
intermedi
prior
viru
spike
viru
spike
exceed
volum
product
intermedi
stabil
concentr
manufactur
specif
sampl
remov
variou
time
point
titrat
assay
use
appropri
viru
cell
assay
system
tabl
dhbv
viru
belong
standard
panel
virus
studi
duckl
temperatur
monitor
calibr
thermocoupl
place
control
tube
contain
similar
volum
pasteur
intermedi
viru
titrat
perform
immedi
test
sampl
gener
viru
titrat
perform
standard
micropl
assay
sampl
assay
control
exampl
posit
assay
control
serial
dilut
cell
cultur
medium
infect
titer
standard
error
sampl
calcul
accord
arber
method
lower
detect
limit
lod
ml
spike
pasteur
undilut
test
sampl
inocul
cell
cultur
flask
test
infecti
viru
largevolum
test
confid
limit
titrat
within
log
viru
rf
gener
report
one
two
way
infect
detect
replic
run
infect
level
lod
indic
largest
rf
select
demonstr
rf
limit
viru
load
spike
start
materi
lod
assay
least
one
replic
run
result
residu
infect
mean
rf
calcul
cytotox
interfer
product
intermedi
capac
virus
infect
cell
evalu
observ
mitig
dilut
sampl
noninocul
cell
serv
neg
control
spike
nonpasteur
intermedi
serv
posit
control
titer
use
calcul
viru
rf
obtain
condit
matrix
interfer
log
assay
perform
cytotox
product
intermedi
observ
hsa
stabil
compon
affect
inactiv
kinet
rang
virus
capryl
nacetyltryptophan
effect
ie
viru
rf
order
log
greater
viru
reduct
capac
could
demonstr
virus
studi
cover
wide
rang
human
pathogen
virus
specif
model
virus
residu
infect
observ
latest
hour
pasteur
anim
parvoviru
cpv
show
resist
heat
treatment
contrast
relev
human
pathogen
viru
tabl
viru
reduct
capac
pasteur
inactiv
hiv
bvdv
prv
hav
cpv
coagul
factor
concentr
inhibitor
protein
perform
accord
standard
manufactur
condit
shown
tabl
kinet
viru
inactiv
product
intermedi
shown
fig
overal
kinet
similar
viru
independ
product
intermedi
studi
hiv
inactiv
level
lod
within
hour
rf
least
log
except
inhibitor
concentr
intermedi
residu
infect
observ
hour
rf
least
log
hour
fastest
inactiv
kinet
hiv
observ
product
intermedi
f
ixfx
rf
least
log
within
hour
bvdv
inactiv
level
lod
latest
within
hour
rf
least
log
inactiv
kinet
compar
product
intermedi
herpesvirus
employ
nonspecif
model
virus
inactiv
effect
pasteur
differ
herpesvirus
belong
differ
herpesviru
genera
speci
show
vari
inactiv
kinet
pasteur
human
herpesviru
hsv
rapidli
complet
inactiv
rf
approxim
log
wherea
porcin
herpesviru
prv
genu
varicelloviru
gener
show
partial
heat
resist
process
intermedi
stabil
sucros
viru
rf
gener
order
log
limit
data
set
avail
genu
cytomegaloviru
genu
varicelloviru
genu
varicelloviru
pasteur
standard
stabil
sucros
glycin
potassium
acet
tabl
rapid
inactiv
kinet
demonstr
hsv
wherea
prv
belong
genu
prv
inactiv
slower
rate
fig
contrast
herpesvirus
studi
envelop
virus
studi
inactiv
kinet
prv
depend
sucros
concentr
fig
interestingli
addit
prv
stabil
nonheat
product
intermedi
result
rapid
reduct
viru
titer
approxim
log
data
shown
vivo
infect
studi
use
duckl
dhbv
inactiv
lod
duck
infect
assay
hour
pasteur
result
viru
rf
least
log
emerg
virus
respect
model
virus
studi
stabil
vwffviii
flavivirus
wnv
yfv
influenza
virus
bunyaviru
lacv
coronavirus
sarscov
tgev
effect
inactiv
virus
demonstr
residu
infect
detect
hour
fig
nonenvelop
viru
hav
inactiv
heat
treatment
reliabl
effect
half
product
intermedi
evalu
residu
infect
detect
end
pasteur
rf
least
log
rf
product
intermedi
rang
log
low
level
residu
infect
remain
tabl
nonenvelop
viru
cpv
heatresist
anim
parvoviru
inactiv
order
log
hour
wherea
human
pathogen
parvoviru
effect
inactiv
approx
log
product
intermedi
except
antithrombin
atiii
api
tabl
reduct
factor
robust
studi
increas
stabil
concentr
spike
temperatur
product
specif
shown
tabl
obviou
impact
inactiv
kinet
viru
rf
observ
hiv
bvdv
mean
differ
rf
temperatur
product
specif
product
intermedi
studi
signific
prv
log
nonsignificantli
lower
hav
log
cpv
log
increas
stabil
concentr
result
nonsignificantli
mean
lower
viru
rf
prv
log
hav
log
signific
differ
rf
assess
accord
state
rf
log
less
consid
signific
pasteur
initi
establish
effect
viru
inactiv
method
product
process
human
albumin
howev
util
pasteur
manufactur
process
therapeut
protein
prepar
heatsensit
coagul
factor
proteas
inhibitor
immunoglobulin
requir
addit
optim
stabil
select
protect
therapeut
protein
without
simultan
protect
virus
common
stabil
composit
use
within
manufactur
process
sucros
sucroseglycin
sucrosepotassium
acet
combin
although
process
sorbitol
citrat
use
protect
therapeut
protein
tabl
vari
condit
broad
effect
viru
inactiv
usual
achiev
tabl
critic
manufactur
variabl
pasteur
step
includ
temperatur
time
composit
product
intermedi
includ
stabil
protein
composit
critic
variabl
tightli
control
monitor
verifi
qualiti
control
practic
fullscal
commerci
manufactur
process
also
similarli
control
scaledown
viru
valid
studi
manufactur
process
robust
pasteur
step
viru
inactiv
evalu
two
way
demonstr
suscept
divers
varieti
envelop
nonenvelop
virus
heat
treatment
procedur
demonstr
viru
reduct
condit
set
outsid
limit
manufactur
process
viru
inactiv
kinet
log
reduct
could
theoret
imped
lower
temperatur
andor
higher
stabil
concentr
overal
result
demonstr
specif
condit
optim
implement
manufactur
process
pasteur
highli
robust
broadli
effect
viru
inactiv
step
heat
inactiv
method
pasteur
dri
heat
treatment
thermal
destabil
intermolecular
interact
viru
capsid
protein
andor
integr
viru
envelop
relev
therebi
result
loss
virion
capsid
structur
integr
viru
infect
contrast
solventdeterg
capryl
octano
acid
inactiv
method
destabil
destroy
lipid
envelop
viru
capsid
therefor
effect
envelop
virus
pasteur
effect
log
inactiv
famili
member
envelop
virus
studi
evalu
target
robust
condit
envelop
virus
except
prv
inactiv
lod
time
point
product
minimum
provid
margin
safeti
indic
true
viru
inactiv
capac
step
like
higher
repres
log
rf
demonstr
viru
valid
studi
prv
model
herp
virus
larg
dna
envelop
virus
also
effect
inactiv
pasteur
slower
inactiv
kinet
presenc
residu
infect
slower
kinet
rate
prv
inactiv
directli
relat
sucros
concentr
illustr
balanc
viru
inactiv
protect
therapeut
protein
activ
high
sucros
concentr
employ
process
requir
preserv
therapeut
protein
function
human
herp
virus
studi
inactiv
faster
prv
verifi
use
prv
worsecas
model
viru
viru
valid
studi
note
prv
herpesvirus
larg
therefor
effect
remov
small
nm
largepor
nm
viru
filtrat
partit
fraction
step
suscept
inactiv
step
eg
uller
et
al
nonenvelop
virus
suscept
inactiv
pasteur
hav
reliabl
effect
inactiv
heat
treatment
albumin
stabil
product
intermedi
line
publish
data
howev
hav
strain
hm
substrain
report
higher
heat
sensit
substrain
least
pasteur
albumin
studi
use
heatresist
hav
substrain
demonstr
littl
impact
inactiv
kinet
sucros
stabil
product
intermedi
data
shown
manuscript
prepar
nonenvelop
anim
parvovirus
cpv
mvm
show
broad
resist
heat
treatment
log
wherea
slightli
higher
viru
rf
log
achiev
presenc
immunoglobulin
interact
immunoglobulin
viru
may
result
destabil
viru
capsid
similar
describ
heat
treatment
human
parvovirus
contrast
human
pathogen
parvoviru
effect
inactiv
product
intermedi
consist
previou
data
except
atiii
intermedi
high
sucros
cacl
concentr
may
factor
stabil
line
boschetti
et
al
viru
reduct
step
within
biolog
manufactur
process
import
part
broad
complementari
safeti
measur
serv
proactiv
measur
emerg
virus
screen
may
asymptomat
donor
broad
effect
pasteur
emerg
virus
virus
concern
evalu
multitud
viru
valid
studi
confirm
pasteur
plasmaderiv
product
consid
safe
regard
emerg
virus
pasteur
effect
flavivirus
wnv
yfv
coronavirus
sarscov
tgev
influenzavirus
bunyaviru
lacv
togavirus
sinv
sfv
fig
consist
publish
data
tbev
chikungunya
viru
zikv
notabl
bvdv
use
standard
model
viru
hcv
viru
valid
tbev
yfv
studi
demonstr
heat
stabl
emerg
virus
fig
therefor
confirm
use
bvdv
worsecas
model
viru
arbovirus
provid
confid
arthropodborn
virus
exampl
dengu
viru
would
also
effect
inactiv
inactiv
hev
reemerg
viru
concern
current
evalu
wide
varieti
stabil
product
intermedi
publish
separ
base
data
present
publish
current
mani
complementari
safeti
measur
place
prevent
transmiss
bloodborn
virus
administr
commerci
plasmaderiv
product
measur
includ
licens
blood
plasma
collect
center
appropri
epidemiolog
regard
hiv
hcv
hbv
plasma
donor
mandatori
voluntari
test
donat
virus
well
hav
high
titer
releas
plasma
pool
fraction
manufactur
nonreact
viru
marker
exceed
dna
iuml
implement
effect
viru
reduct
step
manufactur
process
plasmaderiv
product
base
measur
risk
transmit
bloodborn
virus
via
administr
plasmaderiv
product
remot
demonstr
breadth
studi
present
herein
pasteur
highli
effect
viru
inactiv
step
provid
effect
robust
safeti
measur
known
emerg
envelop
nonenvelop
virus
conclus
pasteur
proven
method
inactiv
wide
rang
envelop
nonenvelop
virus
differ
physicochem
properti
togeth
appropri
select
donor
donat
plasma
pool
manufactur
step
reduc
virus
potenti
present
start
materi
pasteur
plasmaderiv
product
high
safeti
margin
respect
viru
transmiss
demonstr
viru
valid
studi
confirm
ongo
hemovigil
addit
support
inform
may
found
onlin
version
articl
tabl
virus
cell
line
use
pasteuris
studi
